Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: Pulmonary metastases continue to be a significant problem in osteosarcoma. Apoptosis dysfunction is known to influence tumor development. Fas (CD95, APO-1)/FasL is one of the most extensively studied apoptotic pathways. Because FasL is constitutively expressed in the lung, cells that express Fas should be eliminated by lung endothelium. Cells with low or no cell surface Fas expression may be able to evade this innate defense mechanism. The purpose of these studies was to evaluate Fas expression in osteosarcoma lung metastases and the effect of gemcitabine on Fas expression and tumor growth. Experimental Design and Results: Using the K7M2 murine osteosarcoma model, Fas expression was quantified using immunohistochemistry. High levels of Fas were present in primary tumors, but no Fas expression was present in actively growing lung metastases. Blocking the Fas pathway using Fas-associated death domain dominant-negative delayed tumor cell clearance from the lung and increased metastatic potential. Treatment of mice with aerosol gemcitabine resulted in increased Fas expression and subsequent tumor regression. Conclusions: We conclude that corruption of the Fas pathway is critical to the ability of osteosarcoma cells to grow in the lung. Agents such as gemcitabine that up-regulate cell surface Fas expression may therefore be effective in treating osteosarcoma lung metastases. These data also suggest that an additional mechanism by which gemcitabine induces regression of osteosarcoma lung metastases is mediated by enhancing the sensitivity of the tumor cells to the constitutive FasL in the lung.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., Gorlick, R., Hewitt, S. M., & Helman, L. J. (2004) · Nature Medicine · doi:10.1038/nm982 · Cited by 705
Self-citationFas Ligand: A Sensor for DNA Damage Critical in Skin Cancer Etiology
Hill, L. L., Ouhtit, A., Loughlin, S. M., Kripke, M. L., Ananthaswamy, H. N., & Owen-Schaub, L. B. (1999) · Science · doi:10.1126/science.285.5429.898 · Cited by 245
Khanna, C., Prehn, J., Yeung, C., Caylor, J., Tsokos, M., & Helman, L. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1006767007547 · Cited by 207
Self-citationA nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies
Jia, S.-F., Worth, L. L., & Kleinerman, E. S. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006623001465 · Cited by 146
Self-citation
Cited by
Huang, G., Yu, L., Cooper, L. J. N., Hollomon, M., Huls, H., & Kleinerman, E. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2778 · Cited by 127
“We have similarly shown that this FasLþ organ microenvironment is critical to the efficacy of certain chemotherapeutic agents, including gemcitabine and liposomal 9-nitrocamptothecin (31, 32).”
Self-citationZhou, Y., Slone, N., Chrisikos, T. T., Kyrysyuk, O., Babcock, R. L., Medik, Y. B., Li, H. S., Kleinerman, E. S., & Watowich, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000474 · Cited by 112
Self-citationFan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90
The histone deacetylase inhibitor entinostat/syndax 275 in osteosarcoma
Kiany, S., Harrison, D., & Gordon, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_7 · Cited by 24
Self-citationNatural Killer Cell Immunotherapy for Osteosarcoma
Tullius, B. P., Setty, B. A., & Lee, D. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_12 · Cited by 22
Metadata
- Authors
- Gordon, N., Koshkina, N. V., Jia, S.-F., Khanna, C., Mendoza, A., Worth, L. L., & Kleinerman, E. S.
- Venue
- Clinical Cancer Research
- Published
- 2007-08-01
- Volume
- 13
- Issue
- 15
- Pages
- 4503-4510
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2082452180
- Cited by
- 68
- References
- 4
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-0313
- The paper
- Gordon, N., Koshkina, N. V., Jia, S.-F., Khanna, C., Mendoza, A., Worth, L. L., & Kleinerman, E. S. (2007). Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-0313
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.